Navigation Links
Varian, Inc. Reports First Quarter 2008 Results
Date:1/23/2008

the tax impact of the

adjustments described in items (7) - (9) above.

(12) $18,886 and $0.61 per diluted share, respectively, on an adjusted

basis excluding the adjustments (net of related tax effects)

described in items (7) - (9) above.

VARIAN, INC. AND SUBSIDIARY COMPANIES

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

(In thousands, except par value amounts)

December 28, September 28,

2007 2007

------------ ------------

ASSETS

Current assets

Cash and cash equivalents $197,680 $196,396

Accounts receivable, net 175,431 187,429

Inventories 157,843 140,533

Deferred taxes 38,288 38,068

Prepaid expenses and

other current assets 17,114 17,332

------------ ------------

Total current assets 586,356 579,758

Property, plant and equipment, net 108,715 110,792

Goodwill and intangible assets, net 237,202 225,332

Other assets 20,398 20,951

------------ ------------

Total assets $952,671 $936,833

============ ============

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities

Current portion of long-term debt $6,250 $6,250

Accounts payable
'/>"/>

SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
(Date:3/4/2015)... SANTA BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... regulatory consulting firm in the life sciences industry, hired ... Compliance. Blewitt leads the Cloud Compliance Services and ... sciences companies utilize cloud based applications while maintaining compliance ... 20 years, Blewitt has been an accomplished life sciences ...
(Date:3/4/2015)... CALGARY , March 4, 2015 /CNW/ ... that it has completed a collaborative research ... quantitative analytics.  Using Fast Collective Evolution Technology ... dataset including all measurements obtained from each ... Company,s Phase 2 clinical trials ASSERT, SUSTAIN ...
(Date:3/4/2015)... March 4, 2015 AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... breakthrough pain, today announced that it will release ... market close on Monday, March 9th, 2015. AcelRx ... 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) ...
Breaking Biology Technology:Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3
... 17 Today, at the Canadian,Diabetes Association Congress, ... results from a phase 3b clinical study (LEAD(TM) ... The study showed,that liraglutide, a human GLP-1 analog ... blood glucose control (as,measured by HbA1c) than exenatide, ...
... Researchers in a study funded by the National Institutes ... that a direct artificial connection from the brain to ... have been temporarily anesthetized. The results may have ... affected by spinal cord injuries and thousands of others ...
... A team of researchers from Penn State and the University ... use light to control certain proteins that catalyze biochemical reactions. ... successfully controlling the activity of a protein using light," said ... of the Eberly Family Chair in Chemistry, and one of ...
Cached Biology Technology:New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 3New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 4Scientists restore movement to paralyzed limbs through artificial brain-muscle connections 2Scientists restore movement to paralyzed limbs through artificial brain-muscle connections 3Scientists use light to control proteins 2
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/18/2015)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. , Cowen and ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern ... webcasts for these events, please visit Cepheid,s website at ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2
... As researchers around the world hasten to ... that range from manufacturing materials to creating new ... exists. History has shown that previous industrial ... have had some serious environmental impacts. Might ...
... available in Spanish . Studies ... to increase understanding about the environmental factors that regulate ... in oat grain. Avns are one reason oats ... The specific purpose of Avns inside the oat plant ...
... Moines, Iowa February 1, 2010 Efforts will begin ... Rwanda by 21 percent and begin the development of a ... a group of 14 chimpanzees facing extinction. Organizers of the ... will fund reforestation of 647 acres (262 hectares) in the ...
Cached Biology News:Engineers explore environmental concerns of nanotechnology 2Engineers explore environmental concerns of nanotechnology 3Engineers explore environmental concerns of nanotechnology 4Engineers explore environmental concerns of nanotechnology 5Studies provide insight into key oat chemical 2Rwanda's Forest of Hope to expand by 21 percent, begin corridor for endangered chimpanzees 2Rwanda's Forest of Hope to expand by 21 percent, begin corridor for endangered chimpanzees 3
...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
Biology Products: